Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 868 posts found.

NHS image

Cancer Drugs Fund to stay, government to announce

September 27, 2013
Medical Communications, Sales and Marketing CDF, Cameron, NHS, NICE, VBP, prime minister

The UK’s prime minister is set to announce that the controversial Cancer Drugs Fund will remain in place after March …

News
Xalkori image

NICE: final ‘no’ for Xalkori

September 25, 2013
Sales and Marketing NICE, NSCLC, Pfizer, Xalkori

Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …

News
Avastin packshot

UK pharma teams up for better cancer drug access

September 20, 2013
Medical Communications, Sales and Marketing Cancer Drugs Fund, NICE, Novartis, Roche, Sanofi, avastin, no

News
nice_sign

NICE: we need more Aubagio data

September 18, 2013
Sales and Marketing Aubagio, Genzyme, MS, NICE, Sanofi

News
NICE image

NICE queries pharma R&D costs

September 5, 2013
Research and Development, Sales and Marketing Dillon, NICE, Pfizer, R&D

NICE has questioned whether pharma really spends as much as it says it does on bringing new treatments to market …

News
NICE image

Rare disease drugs ‘need separate budget’

September 3, 2013
Research and Development, Sales and Marketing NHS, NICE, rare diseases

A group of MPs in the UK are calling for a ring-fenced fund to pay for drugs for rare and …

News
nice_sign

ThromboGenics/Novartis’ Jetrea gains NICE ‘yes’

August 30, 2013
Alcon, Jetrea, NICE, Novartis, ThromboGenics

News

Afinitor too costly for NICE despite price cut

August 29, 2013
Sales and Marketing Afinitor, HER2 negative, NICE, Novartis, breast cancer

News
NICE image

‘Inequality’ for Welsh cancer patients

August 28, 2013
Sales and Marketing CDF, Cancer, England, NHS, NICE, Wales

Cancer sufferers in England are four times more likely to receive newer treatments on the NHS than patients in Wales, …

News
xalkori image

Price cut not enough for Pfizer’s Xalkori

August 16, 2013
Sales and Marketing NICE, Pfizer, Xalkori, lung cancer

In final draft guidance NICE has rejected Pfizer’s new lung cancer drug Xalkori because of its high cost. The Institute …

News
NICE image

AllTrials campaign releases manifesto

August 9, 2013
Medical Communications, Research and Development, Sales and Marketing Bad pharma, GSK, Goldacre, NICE, transparency

The UK clinical trial transparency initiative AllTrials has released its first detailed manifesto as it looks to ramp up pressure …

News
Perjeta image

Roche breast cancer drug Perjeta rejected by NICE

August 6, 2013
Sales and Marketing Cancer, NICE, Perjeta, Roche

NICE is not recommending Roche’s next generation breast cancer drug Perjeta as a treatment for a particular type of advanced …

News
finbarr-martin-bw

Two non-executive directors join NICE Board

July 26, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing DoH, NICE, finbarr martin, mumford

The Department of Health has announced that two new non-executive directors will join the National Institute for Health and Care …

Appointment
Benlysta image

Benlysta once again rejected by NICE

July 25, 2013
Sales and Marketing Benlysta, GSK, NHS, NICE

NICE has opened a second public consultation for GSK’s lupus drug Benlysta after the Institute has again rejected the medicine …

News
Mabthera image

NICE ‘no’ for MabThera

July 23, 2013
Sales and Marketing MabThera, NHS, NICE, Roche

Roche has been dealt a blow by NICE, with the health watchdog deciding that MabThera should not be used on …

News
The Gateway to Local Adoption Series

Latest content

NICE backs atogepant for acute migraine treatment

June 12, 2026

Survey data highlight challenges in anaphylaxis treatment adherence

June 11, 2026

Hansa Biopharma appoints Fredrik Röök as VP Business Development

June 11, 2026

Sofinnova and AWS collaborate on AI tools for life sciences

June 10, 2026

First European approval given to non-opioid treatment for chronic low back pain

June 9, 2026